Markers for disease and disease extent in inflammatory bowel disease

A method for determining a presence of pancolitis in a subject with ulcerative colitis comprising:

• providing a gut sample obtained from a subject with ulcerative colitis;
• measuring in said gut sample one or more proteins, wherein said one or more proteins comprises at least one of:
• leukotriene A-4 hydrolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein, and thymosin beta-10;
• and
• comparing said measured level to a predetermined protein level to provide an indication of the presence or absence of pancolitis.

A method for determining the efficacy of a treatment of inflammatory bowel disease, said treatment comprising the administration of aminosalicylates, immunomodulators, anti-integrins, anti-cytokines, enteral feed programs, corticosteroids, antibiotics, monoclonal antibodies or a combination thereof, said method comprising:

• measuring a level in an indicative gut sample, obtained from a patient, of one or more proteins, wherein said one or more proteins comprises at least one of:
• leukotriene A-4 hydrolase, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-;
• and
• comparing said measured level to at least one of:
• a corresponding protein level measured in a reference gut sample taken from said patient at a time prior to when said indicative gut sample was obtained;
• a predetermined protein level;
• a corresponding protein level associated with responders;
• and
• a corresponding protein level associated with non-responders;
• and
• assessing responsiveness to treatment as a function of said comparison.

A method for determining the efficacy of a treatment of ulcerative colitis, said treatment comprising the administration of aminosalicylates, immunomodulators, anti-integrins, anti-cytokines, enteral feed programs, corticosteroids, antibiotics, monoclonal antibodies or a combination thereof, said method comprising:

• measuring a level, in a gut sample obtained from a patient with ulcerative colitis, of one or more proteins, wherein said one or more proteins comprises at least one of:
• leukotriene A-4 hydrolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein, and thymosin beta-10;
• comparing said measured level in said gut sample to a predetermined protein level to indicate the presence or absence of pancolitis;
• and
• assessing responsiveness of treatment with reference to a prior health condition of said patient wherein one of:
• said assessment is indicative of responsiveness to treatment when said prior health condition was that said patient had pancolitis and said comparing said measured level in said gut sample indicates an absence of pancolitis;
• and
• said assessment is indicative of non-responsiveness to treatment when said prior health condition was that said patient did not have pancolitis and said comparing said measured level in said gut sample indicates a presence of pancolitis.

A method for determining a presence of inflammatory bowel disease in a subject comprising:

• providing a gut sample obtained from a subject;
• measuring a level in said gut sample of two or more proteins, wherein said two or more proteins comprises at least two of:
• leukotriene A-4 hydrolase, Annexin A3, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-10;
• and
• comparing said measured level to a predetermined protein level to provide an indication of presence of disease.